by | Apr 26, 2024 | Publications
Thromb Res. 2024 Apr 12;238:37-40. doi: 10.1016/j.thromres.2024.04.008. Online ahead of print. NO ABSTRACT PMID:38663044 | DOI:10.1016/j.thromres.2024.04.008
by | Apr 26, 2024 | Publications
Leuk Res. 2024 Feb 1;141:107451. doi: 10.1016/j.leukres.2024.107451. Online ahead of print. ABSTRACT BACKGROUND: Circular RNAs (circRNAs) are associated with development and progression of multiple myeloma (MM). However, the role and mechanism of circ_0005615 in MM...
by | Apr 26, 2024 | Publications
Discov Med. 2024 Apr;36(183):721-729. doi: 10.24976/Discov.Med.202436183.68. ABSTRACT BACKGROUND: Multiple myeloma (MM) is a malignant disorder of plasma cells in the bone marrow. MM causes the clonal proliferation of terminally differentiated plasma cells and the...
by | Apr 26, 2024 | Publications
Biochem Med (Zagreb). 2024 Jun 15;34(2):020801. doi: 10.11613/BM.2024.020801. Epub 2024 Apr 15. ABSTRACT Less than 2% of all symptomatic multiple myeloma (MM) has immunoglobulin D (IgD) as monoclonal protein. Biclonal gammopathy is much rarer. At the time of...
by | Apr 26, 2024 | Publications
Front Oncol. 2024 Apr 11;14:1291055. doi: 10.3389/fonc.2024.1291055. eCollection 2024. ABSTRACT BACKGROUND: Multiple myeloma is diagnosed in 5,800 people in the United Kingdom (UK) each year with up to 64% having vertebral compression fractures at the time of...
by | Apr 25, 2024 | Publications
Blood. 2024 Apr 24:blood.2023022823. doi: 10.1182/blood.2023022823. Online ahead of print. ABSTRACT Teclistamab, an off-the-shelf B-cell maturation antigen (BCMA) × CD3 bispecific antibody that mediates T-cell activation and subsequent lysis of BCMA-expressing myeloma...